A prospective cohort study on decreased serum apelin-13 levels after human aneurysmal subarachnoid hemorrhage: associations with severity and prognosis

• Published in: Neurosurgical review 2023-09, Vol.46 (1), p.235-235, Article 235
• Main Authors: Lin, Qun, Ye, Liangzhi, Dai, Junxia, Ye, Zhengrong, Ba, Huajun, Li, Zhiwei, Chen, Xiaoxiang, Chen, Maohua, Lu, Chuan, Sun, Jun, Cai, Jianyong
• Format: Article
• Language: English
• Subjects: Cerebral Infarction; Humans; Medicine; Medicine & Public Health; Neurosurgery; Prognosis; Prospective Studies; Subarachnoid Hemorrhage
• ISSN: 1437-2320; 1437-2320
• DOI: 10.1007/s10143-023-02142-w

Apelin-13 may have neuroprotective effects. We aimed to determine whether serum apelin-13 could serve as a potential biomarker for severity, delayed cerebral ischemia (DCI), and prognosis after human aneurysmal subarachnoid hemorrhage (aSAH). In this prospective, observational, cohort, single-center study of 139 patients with aSAH and 139 healthy individuals, serum apelin-13 levels were determined. The indicators of stroke severity were the Hunt-Hess scale and the modified Fisher grading scale. The prognostic parameters were DCI and 6-month worse prognosis (Extended Glasgow Outcome Scale scores of 1–4). Using binary logistic regression analysis, the relationship between serum apelin-13 levels and prognosis was reported as odds ratios (ORs) with 95% confidence intervals (CIs). Under the receiver operating characteristic curve, prognostic abilities were shown as areas under the curve (AUCs) with 95% CIs. Serum apelin-13 levels were substantially lower in patients than in controls (median, 28.8 versus 48.6 ng/ml; P